Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

NMTC NeuroOne Medical Technologies Corporation Common Stock
$2.03 -5.58% -0.12
Notify me if price changes either direction
Interactive Brokers Logotype

Buy NMTC stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 18.5M
Enterprise value 17.7M
Trailing PE -3.8333332097089
Forward PE -7.3214283
PEG Ratio 0.11500163917183
Enterprise to EBITDA -2.31
Enterprise to revenue 1.42
Price to book MRQ 4.734411
Price to sales TTM 1.497092

Financials

Fiscal Year Ends 2025-09-30
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 12.5M
EBITDA -7663002
Diluted EPS TTM -0.97
Total Cash (MRQ) 2.0M
Current ratio (MRQ) 2.836
Operating Cash Flow (TTM) -7052007

NMTC trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent NMTC News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.